Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Ltd has announced Matthew Pringle as a new director as of September 6, 2024, according to their Initial Director’s Interest Notice submitted to the ASX. Pringle currently holds no securities within the company either as a registered holder or indirectly. No interests in any contracts related to Clinuvel Pharmaceuticals were disclosed.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
